In the U.S., about 40 percent of adults have obesity, with nearly one in 10 of those individuals considered severely obese, which is defined as a BMI of 40 or higher, according to the agency
These effects resolve with dose reduction but indicate levels beyond physiological optimization
Participants in these studies who used the oral weight loss medication, combined with lifestyle changes like diet and exercise, achieved more substantial weight loss compared to a placebo group
PharmaNutrition, 16 , 100266
Tirzepatide: Another Relevant Comparison Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist approved by the FDA, provides another useful reference point
F., Fransen, P., De Munck, D